NYSE: BFLYButterfly Network Inc Stock
$2.34-0.06 (-2.5%)
Updated Apr 30, 2025
BFLY Price
$2.34
Fair Value Price
N/A
Market Cap
$568.44M
52 Week Low
$0.82
52 Week High
$4.98
P/E
-6.88x
P/B
3.37x
P/S
8.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$82.06M
Earnings
-$72.49M
Gross Margin
59.5%
Operating Margin
-86.85%
Profit Margin
-88.3%
Debt to Equity
0.52
Operating Cash Flow
-$42M
Beta
1.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BFLY Overview
Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; and Butterfly iQ+, a point-of-care ultrasound imaging device that connects with a smart phone or tablet. The company serves healthcare practitioners. Butterfly Network, Inc. was founded in 2011 and is headquartered in Guilford, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BFLY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
BFLY
Ranked#46 of 108
Ranked#46 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.31 | A | |
| $23.03 | A | |
| $14.12 | A |
Be the first to know about important BFLY news, forecast changes, insider trades & much more!
BFLY News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BFLY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BFLY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BFLY is good value based on its book value relative to its share price (3.37x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
BFLY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BFLY due diligence checks available for Premium users.
Valuation
BFLY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.88x
Industry
37.39x
Market
29.18x
BFLY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.37x
Industry
3.94x
BFLY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BFLY's financial health
Profit margin
Revenue
$22.4M
Net Income
-$18.1M
Profit Margin
-81%
BFLY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BFLY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$256.1M
Liabilities
$87.3M
Debt to equity
0.52
BFLY's short-term assets ($192.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BFLY's short-term assets ($192.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BFLY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BFLY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
-$408.0k
Financing
-$1.5M
BFLY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BFLY vs Medical Device Stocks
Butterfly Network Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.